Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Epithelial Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Epithelial Neoplasm

Cancer Family

Epithelial Neoplasm

CI-CAN-00000016Explore in graph →

Non-malignant7,531 active trials118 approved drugs1,152 evidence items

NCIt: C3709

Overview
Statistics
Survival
Genomics314
Variants & evidence1152
Drugs206
Trials26887
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (916)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–225 of 916 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients.
· JNCI Cancer Spectr · 2020 · PMID 32328562 · validated civic_curation pubmed
Midline carcinoma of children and young adults with NUT rearrangement.
· J Clin Oncol · 2004 · PMID 15483023 · validated civic_curation pubmed
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
· Science · 2015 · PMID 25765070 · validated cbioportal_study pubmed
Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels.
· JAMA Oncol · 2022 · PMID 35708671 · validated civic_curation pubmed
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab.
· Nat Med · 2018 · PMID 30082870 · validated civic_curation pubmed
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
· N Engl J Med · 2018 · PMID 29658845 · validated civic_curation pubmed
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
· JAMA Oncol · 2019 · PMID 30816954

Showing 201–225 of 916 publications

← Previous
1
…
8
9
10
…
37
Next →

· validated civic_curation

Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

· JCO Precis Oncol · 2025 · PMID 41100773 · validated civic_curation pubmed

Circulating tumor DNA-based stratification strategy for chemotherapy plus PD-1 inhibitor in advanced non-small-cell lung cancer.

· Cancer Cell · 2024 · PMID 39255777 · validated civic_curation pubmed

A minority of cases of acinic cell carcinoma of the salivary glands are driven by an NR4A2 rearrangement: the diagnostic utility of the assessment of NR4A2 and NR4A3 alterations in salivary gland tumors.

· Virchows Arch · 2023 · PMID 36469101 · validated civic_curation pubmed

Nuclear NR4A3 Immunostaining Is a Specific and Sensitive Novel Marker for Acinic Cell Carcinoma of the Salivary Glands.

· Am J Surg Pathol · 2019 · PMID 31094928 · validated civic_curation pubmed

On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.

· Mol Cancer · 2022 · PMID 34980131 · validated civic_curation pubmed

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

· Cancer Cell · 2018 · PMID 29657128 · validated cbioportal_study pubmed

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.

· PLoS Med · 2005 · PMID 15696205 · validated civic_curation pubmed

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.

· J Clin Endocrinol Metab · 2008 · PMID 18073307 · validated civic_curation pubmed

Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer.

· Ann Surg Oncol · 2011 · PMID 21594703 · validated civic_curation pubmed

Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma.

· Oncol Lett · 2014 · PMID 24396464 · validated civic_curation pubmed

Genome sequencing identifies a basis for everolimus sensitivity.

· Science · 2012 · PMID 22923433 · validated civic_curation pubmed

Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.

· Clin Cancer Res · 2008 · PMID 18794081 · validated civic_curation pubmed

Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.

· J Thorac Oncol · 2014 · PMID 24736073 · validated civic_curation pubmed

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

· N Engl J Med · 2005 · PMID 15728811 · validated civic_curation pubmed

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

· Neoplasia · 2009 · PMID 19794967 · validated civic_curation pubmed

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

· J Clin Oncol · 2001 · PMID 11208838 · validated civic_curation pubmed

Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation.

· Lung Cancer · 2007 · PMID 17070615 · validated civic_curation pubmed

Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer.

· J Thorac Oncol · 2014 · PMID 24662454 · validated civic_curation pubmed